SCHEMBL3460684

SCHEMBL3460684

Nc1ncc(-c2cccc(C(=O)NCc3ccccc3)c2)nc1C(=O)NCCNS(=O)(=O)c1ccccn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ATR Q13535 13/20 0.50
▸ LDHA P00338 1/20 0.47
▸ LDHB P07195 1/20 0.47
▸ PIK3CD O00329 2/20 0.45
▸ PIK3CA P42336 2/20 0.45
▸ PIK3CG P48736 2/20 0.45
▸ PIK3CB P42338 1/20 0.45
▸ PRKDC P78527 2/20 0.44
▸ ATM Q13315 1/20 0.44
▸ JAK2 O60674 1/20 0.44
▸ MAP4K4 O95819 1/20 0.44
▸ CHEK2 O96017 1/20 0.44
▸ PRKCG P05129 1/20 0.44
▸ CDK1 P06493 1/20 0.44
▸ FES P07332 1/20 0.44
▸ RET P07949 1/20 0.44
▸ ROS1 P08922 1/20 0.44
▸ FER P16591 1/20 0.44
▸ FLT1 P17948 1/20 0.44
▸ AXL P30530 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3461935 0.95 ATR (0.49) ATRLDHALDHBPIK3CDPIK3CA
SCHEMBL3460052 0.87 SMN1; SMN2 (0.48) ATRLDHALDHBPIK3CDPIK3CA
SCHEMBL3461970 0.84 ATR (0.56) ATRLDHALDHBPRKDCJAK2
SCHEMBL3460800 0.83 ATR (0.57) ATRLDHALDHBPRKDCJAK2
SCHEMBL3461305 0.83 ATR (0.58) ATRLDHALDHBPRKDCJAK2
SCHEMBL3461813 0.83 SMN1; SMN2 (0.47) ATRLDHALDHBPIK3CDPIK3CA
SCHEMBL3461865 0.82 ATR (0.52) ATRLDHALDHBPRKDCJAK2
SCHEMBL3461585 0.82 ATR (0.56) ATRLDHALDHBPRKDCJAK2
SCHEMBL3460196 0.81 ATR (0.54) ATRLDHALDHBPRKDCJAK2
SCHEMBL3461683 0.81 ATR (0.54) ATRLDHALDHBPRKDCJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 — — US claimed
EP-1501514-B1 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2012-12-19 — — EP disclosed
US-7704995-B2 Protein kinase modulators and methods of use EXELIXIS, INC. (US) 2010-04-27 — — US disclosed
EP-1501514-A4 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS INC (US) 2009-08-26 — — EP disclosed
US-20060211709-A1 Protein kinase modulators and methods of use EXELIXIS, INC. 2006-09-21 — — US disclosed
EP-1501514-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE Exelixis, Inc. (US) 2005-02-02 — — EP disclosed
WO-2003093297-A2 PROTEIN KINASE MODULATORS AND METHODS OF USE EXELIXIS, INC. (US) 2003-11-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060211709-A1 Protein kinase modulators and methods of use GRK2, MAP4K2, MAPKAPK2 ATR 556/4885LDHA 2158/4885LDHB 2891/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback